Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Impel Pharmaceuticals Inc.

Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system (CNS), through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. 

Impel Pharmaceuticals

Summer is a tough time of year for #migraine and #headaches. To best celebrate #freedom with your friends and family, be mindful of your triggers and keep your acute meds on hand.
 
Wishing everyone a safe and happy #IndependenceDay!

Trudhesa® (DHE mesylate) delivers a trusted #migraine therapeutic to the vascular-rich upper nasal space via the POD® device developed by our co-founder, CTO & CDO, John Hoekman. This results in IV-like efficacy at home - not via injection in an ER.

The Impel team proudly supports the #migraine community. Today we're wearing our #ShadesForMigraine to raise awareness about this complex, neurological disease that's more than just a #headache. 

#MHAM #MigraineAwareness

A second poster on preliminary real-world data underscores the need for non-oral treatment options for #migraine given the prevalence of pre-existing #gastrointestinal disorders among those prescribed with Trudhesa® (DHE mesylate).

See abstract P-160 in Headache: https://lnkd.in/eV8n_mNw

Read our press release to learn more: https://lnkd.in/eEkwReSh

#MHAM Dr. Sheena Aurora

Preliminary real-world data at #AHSAM suggest that concomitant preventive & acute medication use generally decreases in patients taking Trudhesa® (DHE mesylate) nasal spray, and that use of antinausea medications (common with DHE administered via IV) did not increase.

See abstract P-161 in Headache: https://lnkd.in/eV8n_mNw

Read yesterday's press release to learn more: https://lnkd.in/eEkwReSh 

#Migraine #MHAM Zubair Ahmed

	Dec '19	Dec '20	Dec '21	Dec '22
asset turnover			0.01 -	0.14 1,994.26%
cash conversion cycle			-1.13K -	345.97 130.54%
cash per share	2.82 -	0.54 80.82%	6.04 1,018.85%	2.59 57.18%
company equity multiplier	-0.46 -	-0.09 80.40%	1.86 2,164.34%	-2.01 207.54%
days of inventory outstanding			1.49K -	473.57 68.25%
days of payables outstanding			3.36K -	342.35 89.82%
days of sales outstanding			738.74 -	214.75 70.93%
dividend yield
ebit per revenue			-107.01 -	-6.57 93.86%
ebt per ebit	1.01 -	1.01 0.39%	1.07 5.98%	1.28 19.37%
effective tax rate	-0.00 -	-0.00 96.96%	-0.00 19.68%	-0.22 832,392.26%
enterprise value multiple	-3.92 -	-4.48 14.38%	-0.94 79.02%	-0.94 0.27%
fixed asset turnover			0.21 -	1.81 752.64%
free cash flow per share	-2.89 -	-3.12 7.77%	-4.57 46.68%	-4.05 11.38%
gross profit margin			-0.03 -	0.49 1,513.38%
interest coverage				-6.01 -
inventory turnover			0.24 -	0.77 214.99%
long term debt to capitalization		-0.06 -	0.36 664.15%	9.05 2,417.49%
net income per ebt	1.00 -	1.00 0.07%	1.00 0.00%	1.22 21.75%
net profit margin			-114.57 -	-10.23 91.07%
operating cash flow per share	-2.78 -	-2.98 7.39%	-4.55 52.42%	-3.99 12.13%
operating cycle			2.23K -	688.33 69.14%
operating profit margin			-107.01 -	-6.57 93.86%
payables turnover			0.11 -	1.07 882.37%
pretax profit margin			-114.57 -	-8.40 92.67%
price fair value	-2.15 -	-1.48 31.31%	2.40 262.55%	-1.99 182.97%
receivables turnover			0.49 -	1.70 244.00%
return on assets	-0.99 -	-3.80 283.47%	-0.78 79.42%	-1.46 87.00%
return on capital employed	-1.22 -	-29.57 2,314.87%	-0.87 97.05%	-1.25 43.66%
return on equity	0.46 -	0.34 24.84%	-1.46 524.89%	2.93 301.11%
total debt to capitalization		-0.07 -	0.36 634.40%	7.28 1,926.58%

COM:IMPELPHARMA

Impel Pharmaceuticals Inc.

Last Close

0.06

20/12 20:58

Market Cap

956K

Beta: -

Volume Today

720.03K

Avg: -

Preview